CroíValveAnnounced the completion of a $16 million Series B financing round. This round was led by MedTech & Irrus Syndicates, with participation from Ascentifi, Furthr, Broadview Ventures,Atlantic Bridge University Fund、Enterprise Ireland, Elkstone & SOSV, and IAG Capital Partners followed with investments."This financing round demonstrates the unmet need for treating tricuspid regurgitation and the potential of DUO to treat more patients in a repeatable and intuitive manner. We are excited to bring this technology to the United States, backed by strong support from our group of shareholders, who are committed to our mission of transforming the lives of patients with tricuspid regurgitation."---Lucy O'Keeffe CEO of CroíValveThis financing is benefited fromCroíValveDevelopment of Reversible Tricuspid Valve Replacement TechnologyDUOTheFor the first timeClinical Research in Humans (TANDEM I) Demonstrated excellent clinical outcomes. The study results were published in June:Specific Research Data
- Results at six months showed a significant reduction in TR among treated patients, with over 85% experiencing a reduction to moderate or lower.
- Patients' function and quality of life also significantly improved, with KCCQ scores and 6MWT both showing a significant increase from baseline.
- The survival rate of patients at 6 months post-operation was 100%;
- The reported incidence of arrhythmias or conduction disorders that do not require permanent pacing demonstrates the advantage of avoiding right heart contact.
- The data also demonstrate the long-term stable positioning and functionality of the device, while supporting natural reverse remodeling.
- Even in the case of first-time use, the average implantation time for the device was only 43 minutes.
"I believe DUO can simplify the treatment for TR patients and enable predictable procedures using standard imaging techniques. Additionally, with minimal anatomical exclusions, it can cover a broad population. It has the potential to become a meaningful advancement in the field of TR treatment."---Martin B.Leon Columbia University Irving Medical Center College
DUO
DUOIt is a novel transcatheter heart valve that works in synergy with the native tricuspid valve, restoring valve function through an innovative anchoring mechanism without affecting the patient's right heart and native valve.DUOComposed of three parts: stent, connector, and valve.
DUOAimed at assisting the coaptation of dilated tricuspid valve leaflets through a stent.DUOAnchored within the superior vena cava while positioning the valve between the native leaflets to reduce the size of the regurgitant orifice and provide a contact surface for leaflet coaptation. In addition to the simple space-occupying design,DUOIt also has a trileaflet valve structure to support forward blood flow through the tricuspid valve during diastole, which may potentially reduce the risk of device thrombosis.DUOThis new placement and fixation methodAchieved simplification of the surgery.DUODue to the adoption ofSetThis new fixation method, as opposed to the traditional tissue-penetrating anchoring approach, allowsDUOHigher safety, allowingDUOIt is very important to remove it after the operation.（Biological ValveThe short membrane life directly leads to the inability of patients to use it before the year, which is a headache problem).
CroiValveCroíValve is an early-stage medical device company focused on developing minimally invasive devices for the treatment of tricuspid regurgitation. Headquartered in Dublin, Ireland, the founding team brings extensive clinical, technical, and commercial expertise.
